Many features of dyslipidemia are missed by the standard lipid panel. I investigated the use of advanced lipoprotein profiling in the diagnosis of dyslipidemia. I found that normoglycemic first degree relatives of type 2 diabetes (T2D) patients have lower high density lipoprotein (HDL) levels than controls from non T2D families. I also found that the drug lomitapide decreases all atherogenic lipoproteins, but does not affect HDL function.
Lipoprotein (a) (Lp(a)) is a risk factor for the development of cardiovascular disease (CVD), but there are no therapies available yet to solely reduce Lp(a) levels. I investigated the effect of widely used therapies aimed at CVD prevention on Lp(a). I found that both statin treatment and diet-induced weight reduction increase Lp(a) levels. I also found that Lp(a) is increased in heterozygous familial hypercholesterolemia (FH) and even more in homozygous FH compared to non-FH subjects. Future research will still have to define cut-off points for diabetic dyslipidemia using advanced lipoprotein profiling. It still remains to be clarified whether lowering of Lp(a) levels will eventually result in fewer CVD events.

Additional Metadata
Keywords Dyslipidemia, lipoprotein(a), HDL, FH, HoFH, T2D, lipoprotein profile
Promotor E.J.G. Sijbrands (Eric) , M.T. Mulder (Monique) , J.E. Roeters van Lennep (Jeanine)
Publisher Erasmus University Rotterdam
ISBN 978-94-6380-233-8
Persistent URL
Note For copyright reasons there is a partial embargo for this dissertation
Yahya, R. (2019, March 13). Dyslipidemia beyond LDL. Erasmus University Rotterdam. Retrieved from